PMID- 9090785
OWN - NLM
STAT- MEDLINE
DCOM- 19970618
LR  - 20210102
IS  - 1066-5099 (Print)
IS  - 1066-5099 (Linking)
VI  - 15
IP  - 2
DP  - 1997
TI  - Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based 
      antitumor vaccines.
PG  - 94-103
AB  - Dendritic cells (DCs) are considered the most effective antigen-presenting cells 
      (APCs) for primary immune responses. Since presentation of antigens to the immune 
      system by appropriate professional APCs is critical to elicit a strong immune 
      reaction and DCs seem to be quantitatively and functionally defective in the 
      tumor host, DCs hold great promise to improve cancer vaccines. Even though they 
      are found in lymphoid organs, skin and mucosa, the difficulty of generating large 
      numbers of DCs has been a major limitation for their use in vaccine studies. A 
      simple method for obtaining DCs from mouse bone marrow cells cultured in the 
      presence of GM-CSF + interleukin 4 is now available. In four different tumor 
      models, mice injected with DCs grown in GM-CSF plus interleukin 4 and prepulsed 
      with a cytotoxic T lymphocyte-recognized tumor peptide epitope developed a 
      specific cytotoxic T lymphocyte response and were protected against a subsequent 
      tumor challenge with tumor cells expressing the relevant tumor antigen. Moreover, 
      treatment of day 5-14 tumors with peptide-pulsed DCs resulted in sustained tumor 
      regression in five different tumor models. These results suggest that 
      presentation of tumor antigens to the immune system by professional APCs is a 
      promising method to circumvent tumor-mediated immunosuppression and is the basis 
      for ongoing clinical trials of cancer immunotherapy with tumor peptide-pulsed 
      DCs.
FAU - Mayordomo, J I
AU  - Mayordomo JI
AD  - University of Pittsburgh Cancer Institute, Pennsylvania, USA.
FAU - Zorina, T
AU  - Zorina T
FAU - Storkus, W J
AU  - Storkus WJ
FAU - Zitvogel, L
AU  - Zitvogel L
FAU - Garcia-Prats, M D
AU  - Garcia-Prats MD
FAU - DeLeo, A B
AU  - DeLeo AB
FAU - Lotze, M T
AU  - Lotze MT
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
RN  - 0 (Cancer Vaccines)
RN  - 0 (Peptide Fragments)
SB  - IM
MH  - Animals
MH  - Bone Marrow/*immunology
MH  - Bone Marrow Cells
MH  - Cancer Vaccines/*immunology/metabolism
MH  - Combined Modality Therapy
MH  - Dendritic Cells/cytology/*immunology
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Peptide Fragments/*immunology/metabolism
RF  - 59
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1002/stem.150094 [doi]
PST - ppublish
SO  - Stem Cells. 1997;15(2):94-103. doi: 10.1002/stem.150094.